Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Top 10 US Biomedical Research Institutions Involved in Drug Development

By BiotechDaily International staff writers
Posted on 23 Feb 2014
As Big Pharma companies are increasingly slashing their R&D spending, academic research institutions must play a key role in the drug development process, particularly on the preclinical research and drug discovery side.

Whereas many of the research institutions are still doing ample fundamental science research, interest seems to be growing among the universities in repurposing existing drugs or those that never made it into the marketplace because of safety problems, according to recent market research.

FierceBiotech (Washington DC, USA), an online drug development industry publication that monitors biopharmaceutical deals, the US Food and Drug Administration (FDA), and clinical trials, recently reviewed some of the best research institutions in the United States and ranked by them by their level of funding from the US National Institutes of Health (NIH; Bethesda, MD, USA), the largest funder of biomedical research worldwide.

In 2013, funding for biomedical research at these institutions took a hit from sequestration on top of years of budget slashes to the NIH. Out of 10, 7 of those on the list (shown below) lost funding in US fiscal 2013 compared to the same period in 2012. Stanford University, the University of North Carolina at Chapel Hill, and the University of California, San Francisco, were the only 3 among the top 10 to receive a slight cash influx in NIH funding from 2012 to 2013. A 2014 spending bill passed in January 2014 will restore USD 1 billion to NIH compared to fiscal year 2013 postsequester, but that is still below presequester funding levels.

The top ten instituitions: 1. Johns Hopkins University (Baltimore, MD); 2. University of California, San Francisco; 3. University of Washington (Seattle, WA, USA); 4. University of Pennsylvania (Philadelphia); 5. University of Michigan (Ann Arbor); 6. University of Pittsburgh (PA); 7. University of North Carolina at Chapel Hill; 8. University of California, San Diego; 9. Stanford University (Stanford, CA), and 10. Duke University (Durham, NC).

FierceBiotech is a publication of FierceMarkets, a division of Questex Media Group, LLC.

Related Links:

FierceBiotech 
National Institutes of Health



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A scheme for the generation of induced pluripotent stem cells (IPSC). (1) Isolate and culture donor cells. (2) Transfect stem cell-associated genes into the cells by viral vectors. Red cells indicate the cells expressing the exogenous genes. (3)  Harvest and culture the cells using mitotically inactivated feeder cells. (4) A small subset of the transfected cells forms iPSC cell colonies (Photo courtesy of Wikimedia Commons).

Innovative Technique Produces More Reliable Pluripotent Stem Cells

A recent paper described a more reliable way to induce the formation of pluripotent stem cells (iPSCs) from adult cells in a mouse model. Reliable high-quality iPSCs are needed for the development of... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.